Myeloma Paper of the Day, July 18th, Suggested by Robert Orlowski
Robert Orlowski, Deputy Chair of Lymphoma/Myeloma, Vice Chair of MM Research, and Florence Maude Thomas Cancer Research Professor at the University of Texas MD Anderson Cancer Center, shared a post on X:
“Myeloma Paper of the Day:
Case series of teclistamab in myeloma patients with secondary plasma cell leukemia (PCL) shows median PFS of only 27 days (responders had PFS of 4.6 months) and none of those with prior BCMA therapy exposure had a response.”
Title: The Efficacy of Teclistamab in Multiple Myeloma Patients with Secondary Plasma Cell Leukemia
Authors: Asis Shrestha, Sharmilan Thanendrarajan, Aishee Bag, Binod Dhakal, Maurizio Zangari, Samer Al Hadidi, Frits van Rhee, Anita D’Souza, Nishi Shah, Mansi R. Shah, Meera Mohan, Carolina Schinke.
You can read the Full Article in Blood Advances.
You can find more posts featuring Robert Orlowski in OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023